Abstracts tagged "Disease Activity and rheumatoid arthritis (RA)"

Abstract Number: 475 • 2015 ACR/ARHP Annual Meeting
Benefits of Achieving Comprehensive Disease Control (CDC) in Patients with Rheumatoid Arthritis: Evidence from the Corrona Registry
Arthur Kavanaugh¹, Carol J. Etzel^2,3, Wendi Malley³, Chitra Karki³, Jeffrey D. Greenberg^3,4, Yanjun Bao⁵, Naijun Chen⁵ and Vishvas Garg⁶, ¹University of California, San Diego School of Medicine, LaJolla, CA, ²The University of Texas MD Anderson Cancer Center, Houston, TX, ³Corrona, LLC, Southborough, MA, ⁴NYU School of Medicine, New York, NY, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie, North Chicago, IL
Background/Purpose: Based on international task force recommendations, the primary goal of rheumatoid arthritis (RA) treatment is to: achieve control of symptoms to greatest extent possible,…
Abstract Number: 2662 • 2015 ACR/ARHP Annual Meeting
Validation of the Quickdash in the Assessment of Rheumatoid Arthritis Disease Activity
Cassandra Craig¹ and Matthew Carroll², ¹Internal Medicine, Keesler Medical Center, Keesler AFB, MS, ²Rheumatology, Keesler Medical Center, Keesler AFB, MS
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory arthritis associated with substantial morbidity and mortality. Measuring disease activity in RA is important as it…
Abstract Number: 2665 • 2015 ACR/ARHP Annual Meeting
Improved Flare/ Remission Pattern in Rheumatoid Arthritis over the Recent Decades
Elena Myasoedova¹, Sherine E. Gabriel², Eric L. Matteson³, John M. Davis III⁴ and Cynthia S. Crowson⁵, ¹Internal Medicine and Rheumatology, Mayo Clinic, Rochester, MN, ²Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁵Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: Flare or episodic worsening of disease activity is an important aspect of the disease experience for patients with rheumatoid arthritis (RA), with significant impact…
Abstract Number: 2670 • 2015 ACR/ARHP Annual Meeting
Comparison of M-DAS and DAS28, Two Composite Scores for Prediction of Structural Damages in Rheumatoid Arthritis: Data from the Espoir Cohort
Marion Couderc¹, Bruno Pereira², B G Combe³, Valerie Devauchelle⁴, Xavier Mariette⁵ and Martin Soubrier¹, ¹Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ²Biostatistics unit (DRCI), CHU Clermont-Ferrand, Clermont-Ferrand, France, ³Hospital Lapeyronie, Immuno-Rheumatology, Montpellier, France, ⁴Service de Rhumatologie, CHU Brest, Brest, France, ⁵Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France
Background/Purpose: Numbers of composite scores are available to assess disease activity in rheumatoid arthritis (RA), the most widely used being the Disease-Activity-Score in 28 joints…
Abstract Number: 2685 • 2015 ACR/ARHP Annual Meeting
High Levels of 25(OH)D Are Associated with Lower Disease Activity in Patients with Newly Diagnosed Rheumatoid Arthritis
Linda Rasch¹, Nicole Konijn¹, Yvonne Krul-Poel², Lilian van Tuyl¹, Hennie Raterman¹, Marieke ter Wee¹, Debby den Uyl¹, Suat Simsek², Michael Nurmohamed^1,3 and Willem Lems^1,3, ¹Amsterdam Rheumatology and immunology Center, location VU University Medical Center, Department of Rheumatology, Amsterdam, Netherlands, ²Department of Internal Medicine, Medical Center Alkmaar, Alkmaar, Netherlands, ³Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands
Background/Purpose: Vitamin D deficiency is highly common in patients with rheumatoid arthritis (RA) (1). In vitro, vitamin D has anti-inflammatory effects and vitamin D has…
Abstract Number: 1055 • 2014 ACR/ARHP Annual Meeting
Identifying Flare in Rheumatoid Arthritis (RA): Performance of the Flare-Assessment in RA (FLARE) Questionnaire in a US Population
Elena Myasoedova¹, Cynthia S. Crowson², Bruno Fautrel³, Francis Guillemin⁴, Eric L. Matteson⁵ and Sherine E. Gabriel⁶, ¹Internal Medicine and Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France, ⁴Nancy University Hospital, Nancy, France, ⁵Rheumatology, Mayo Clinic, Rochester, MN, ⁶Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose Flare is an important aspect of rheumatoid arthritis (RA) patients’ disease experience with a crucial impact on quality of life and well-being. The flare-assessment…
Abstract Number: 419 • 2014 ACR/ARHP Annual Meeting
Comparative Dynamics of Rheumatoid Arthritis Disease Activity and Disease Severity Measures Using Rarbis, Ciras and DAS28 in a Population Based Cohort of Patients with RA
Arun K. Chandran¹, Cynthia S. Crowson², Birkan İlhan³, C. John Michet III¹, Eric L. Matteson¹ and Elena Myasoedova⁴, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey, ⁴Internal Medicine and Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: There is an extensive list of composite scores of rheumatoid arthritis (RA) activity status for the use in clinical practice including Disease Activity Score…
Abstract Number: 428 • 2014 ACR/ARHP Annual Meeting
Patient-Physician Discordance of Disease Activity Assessments Predicts Inadequate Treatment Response in Early Rheumatoid Arthritis
John M. Davis III¹, Cynthia S. Crowson², Tim Bongartz¹, Clement J. Michet¹, Eric L. Matteson¹ and Sherine E. Gabriel³, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose Discordance between patients’ and physicians’ global assessments of disease activity occurs in up to a third of clinical evaluations for rheumatoid arthritis (RA). In…
Abstract Number: 2866 • 2013 ACR/ARHP Annual Meeting
Determining The Absolute Change In The Clinical Disease Activity Index (CDAI) To Define a Minimally Important Difference
Jeffrey R. Curtis¹, Shuo Yang², Lang Chen³, Janet E. Pope⁴, Edward C. Keystone⁵, Boulos Haraoui⁶, Gilles Boire⁷, J. Carter Thorne⁸, Diane Tin⁹, Carol A. Hitchon¹⁰, Clifton O. Bingham III¹¹ and Vivian P. Bykerk¹², ¹University of Alabama at Birmingham, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴St Joseph Health Care, London, ON, Canada, ⁵Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ⁶Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ⁷Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁸Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ¹¹Rheumatology, Johns Hopkins University, Baltimore, MD, ¹²Divison of Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Simplified measures to quantify rheumatoid arthritis (RA) disease activity are increasing in use in clinical practice. However, the absolute minimally important difference (MID) in…
Abstract Number: 2253 • 2013 ACR/ARHP Annual Meeting
How Often Are Core Variables Reported To Calculate Common Disease Activity Scores Measured In Routine Care Of Rheumatoid Arthritis Patients?
Bindee Kuriya¹, Jessica Widdifield^2,3, Claire Bombardier⁴, Xiuing Li⁵, Binu Jacob⁶, Pooneh Akhavan⁷, J. Carter Thorne⁸, Janet E. Pope⁹, Edward C. Keystone¹⁰, William G. Bensen¹¹ and Vandana Ahluwalia¹², ¹Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ²Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto, ON, Canada, ⁵University of Toronto, University Health Network, Toronto, ON, Canada, ⁶University Health Network, Toronto General Research Institute, Toronto, ON, Canada, ⁷Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ⁸Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹St Joseph Health Care, London, ON, Canada, ¹⁰Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, University of Toronto, Toronto, ON, Canada, ¹¹Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ¹²William Osler Health Center, Brampton, ON, Canada
Background/Purpose: Treat-to-target (T2T) is a therapeutic strategy in rheumatoid arthritis (RA) that has been associated with improved outcomes. T2T relies on objective measurement of disease…
Abstract Number: 1451 • 2013 ACR/ARHP Annual Meeting
Comparison Of Clinical Characteristics Of Patients With Rheumatoid Arthritis Receiving Their First Biologic and Biologic-Naïve Patients Considered Biologic-Suitable In The United States
Siva Narayanan¹, Yao Lu², Richard Hutchings² and Amanda Baskett², ¹Evidence Generation, Value and Access Center, Ipsos Healthcare, Columbia, MD, ²Ipsos Healthcare, London, United Kingdom
Background/Purpose: Data on clinical status of biologic-naïve Rheumatoid Arthritis (RA) patients who are considered suitable for biologic therapy (by their physicians) is lacking. We assessed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].